6,800 Shares in Hims & Hers Health, Inc. $HIMS Bought by Napa Wealth Management

Key Points

• Napa Wealth Management has acquired a new stake in Hims & Hers Health, purchasing 6,800 shares valued at approximately $201,000.
• Several institutional investors have increased their stakes in Hims & Hers Health, with Farallon Capital Management raising its investment by over 64,000%.
• Insider trading activity has seen CEO Andrew Dudum sell 128,127 shares, reducing his ownership by almost 59%, indicating potential shifts in management confidence.

Napa Wealth Management purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,800 shares of the company's stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors have also modified their holdings of HIMS. UMB Bank n.a. boosted its holdings in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Hims & Hers Health during the 1st quarter valued at about $41,000. Larson Financial Group LLC lifted its holdings in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock valued at $42,000 after purchasing an additional 458 shares in the last quarter. Fifth Third Bancorp lifted its holdings in shares of Hims & Hers Health by 165.4% during the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares in the last quarter. Finally, Tsfg LLC acquired a new stake in Hims & Hers Health in the 1st quarter valued at approximately $46,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded up $2.51 during mid-day trading on Tuesday, reaching $45.50. The company had a trading volume of 29,293,931 shares, compared to its average volume of 33,600,738. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of 56.88, a PEG ratio of 3.01 and a beta of 2.08. The business's 50-day simple moving average is $51.37 and its 200 day simple moving average is $45.85. Hims & Hers Health, Inc. has a one year low of $13.47 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's revenue for the quarter was up 72.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $45.06, for a total transaction of $5,773,402.62. Following the sale, the chief executive officer owned 89,521 shares in the company, valued at approximately $4,033,816.26. This trade represents a 58.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Michael Chi sold 2,100 shares of the company's stock in a transaction on Thursday, July 24th. The stock was sold at an average price of $57.52, for a total value of $120,792.00. Following the sale, the insider owned 278,654 shares of the company's stock, valued at approximately $16,028,178.08. This represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,395,428 shares of company stock worth $71,861,486. Insiders own 13.71% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on HIMS. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Finally, Morgan Stanley reissued an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of "Reduce" and an average target price of $38.92.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.